Drugs / Hyzaar®
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | HYZAAR | — | 1995-04-28 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01620788 Comparator | Nov 2019 → Jul 2023 | hypertensive disorder | EMS | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyzaar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01620788 ↗ |
| Route | Oral | “1 tablet of Hyzaar®, oral, a day” NCT01620788 ↗ |